



Morin ameliorates methotrexate-induced hepatotoxicity via targeting Nrf2/HO-1 and Bax/Bcl2/Caspase-3 signaling pathways

Hamit Emre Kızıl¹ · Cuneyt Caglayan² · Ekrem Darendelioğlu³ · Adnan Ayna⁴ · Cihan Gür⁵ · Fatih Mehmet Kandemir⁶ · Sefa Küçükler⁵

Received: 7 December 2022 / Accepted: 17 January 2023 / Published online: 13 February 2023
© The Author(s), under exclusive licence to Springer Nature B.V. 2023

Abstract

Background Organ toxicity limits the therapeutic efficacy of methotrexate (MTX), an anti-metabolite therapeutic that is frequently used as an anti-cancer and immunosuppressive medicine. Hepatocellular toxicity is among the most severe side effects of long-term MTX use. The present study unveils new confirmations as regards the remedial effects of morin on MTX-induced hepatocellular injury through regulation of oxidative stress, apoptosis and MAPK signaling.

Methods and results Rats were subjected to oral treatment of morin (50 and 100 mg/kg body weight) for 10 days. Hepatotoxicity was induced by single intraperitoneal injection of MTX (20 mg/kg body weight) on the 5th day. MTX related hepatic injury was associated with increased MDA while decreased GSH levels, the activities of endogen antioxidants (glutathione peroxidase, superoxide dismutase and catalase) and mRNA levels of HO-1 and Nrf2 in the hepatic tissue. MTX treatment also resulted in apoptosis in the liver tissue via increasing mRNA transcript levels of Bax, caspase-3, Apaf-1 and downregulation of Bcl-2. Conversely, treatment with morin at different doses (50 and 100 mg/kg) considerably mitigated MTX-induced oxidative stress and apoptosis in the liver tissue. Morin also mitigated MTX-induced increases of ALT, ALP and AST levels, downregulated mRNA expressions of matrix metalloproteinases (MMP-2 and MMP-9), MAPK14 and MAPK15, JNK, Akt2 and FOXO1 genes.

Conclusion According to the findings of this study, morin may be a potential way to shield the liver tissue from the oxidative damage and apoptosis.

Keywords Apoptosis · Hepatotoxicity · Methotrexate · Morin · Oxidative stress

Introduction

Methotrexate (MTX), a folate analog and antagonist, is broadly used for the treatment of a variety of malignant and non-malignant disorders [1]. Due to the beneficial anti-inflammatory and immunomodulatory activities it has, MTX is now the firstline disease modifying antirheumatic drug in the treatment of rheumatoid arthritis [2]. MTX was first designed to block the synthesis of purines and pyrimidines, which is essential for synthesis of genetic material as well as the proliferation of a variety of malignant and non-malignant cells. Even though this mechanism may contribute to the mechanism by which MTX suppresses inflammation, other mechanisms of action including increased adenosine release, inhibition of transmethylation reactions essential for some cellular functions, decreased polyamine accumulation and NO synthase uncoupling have been proposed [3]. Despite its beneficial effects, MTX has

✉ Cuneyt Caglayan
cuneyt.caglayan@bilecik.edu.tr

✉ Fatih Mehmet Kandemir
fkandemir03@gmail.com

¹ Vocational School of Health Services, Bayburt University, Bayburt, Turkey

² Department of Medical Biochemistry, Faculty of Medicine, Bilecik Seyh Edebali University, Bilecik, Turkey

³ Department of Molecular Biology and Genetics, Faculty of Science and Literature, Bingöl University, 12000 Bingöl, Turkey

⁴ Department of Chemistry, Faculty of Science and Literature, Bingöl University, Bingöl, Turkey

⁵ Department of Biochemistry, Faculty of Veterinary Medicine, Atatürk University, Erzurum, Turkey

⁶ Department of Medical Biochemistry, Faculty of Medicine, Aksaray University, Aksaray, Turkey

several major side effects and can cause toxicities in organs such as the liver, kidneys and testes [4–6]. Protecting the organs from undesired side effects could be one way to mitigate the negative consequences of MTX in therapeutic applications. As a result, the protective effects of natural biomolecules with antioxidant activities that may reduce the severity of MTX-induced toxicities could be useful for therapeutic purposes.

Flavonoids are dietary bioactive chemicals obtained from plants that have significant impacts on health. Morin is an important flavonoid derived mostly from the stems, fruits, and leaves of Moraceae plants [7]. The most important advantage of morin as an antioxidant is its low toxicity even at higher dose usage [8]. Numerous studies have shown that morin hydrate is effective against a variety of chronic and life-threatening degenerative disorders [9]. It has been revealed to have anti-inflammatory and antioxidant properties in a range of diseases including cancer [10], hepatotoxicity and nephrotoxicity [11]. In a previous study by our group, the protective effects of morin on doxorubicin-induced hepatotoxicity and nephrotoxicity in rats were demonstrated [12].

The results demonstrate that morin can be beneficial in ameliorating MTX induced liver toxicity by showing antioxidant and anti-apoptotic properties.

Materials and methods

Chemicals

Methotrexate (50 mg/5 mL injectable solution) was obtained Koçak Farma (İstanbul, Turkey). All of the chemicals used in this study, including morin hydrate, were procured from Sigma–Aldrich chemicals (St. Louis, MO, USA) and were of analytical grade.

Animals

Experiments were conducted on 35 male Wistar albino rats (weighing between 280 and 300 g, 11–12 weeks old) obtained from Bingol University's Experimental Research Center. The rats were housed in plastic cages and fed under standard laboratory conditions (12 h light/dark cycle, 24 ± 1 °C, and $45 \pm 5\%$ humidity). They were fed a commercial chow meal and had unrestricted access to water. All animal-related treatments were approved by Bingol University's Animal Experimentation Ethics Committee (Protocol No: 2022-E.66052).

The rats were separated into five groups of 7 male rats each at random:

Control group: The animals received 0.9% saline via oral gavage for 10 days and a single intraperitoneal injection of saline on day 5 only.

Morin group: The animals were given 100 mg/kg morin hydrate orally for 10 days and intraperitoneal saline injection was given on the 5th day of the experiment [12].

MTX group: The animals were administered saline orally for 10 days and on the 5th day of the experiment, a single dose of 20 mg/kg MTX was injected intraperitoneally [13].

MTX + Morin 50 group: Rats were given 50 mg/kg morin hydrate orally for 10 days and a single dose of 20 mg/kg MTX was injected intraperitoneally on the 5th day of the experiment.

MTX + Morin 100 group: Rats were given 100 mg/kg morin hydrate orally for 10 days and a single dose of 20 mg/kg MTX was injected intraperitoneally on the 5th day of the experiment.

Following day, the rats were sacrificed under mild sevoflurane anesthesia. Blood serum was separated by centrifugation at $3000 \times g$ for 10 min, and the serum samples were then tested for liver function analysis. Livers were immediately removed and washed with ice-cold physiological saline solution for biochemical and molecular analysis and then stored at -20 °C.

Measurement of liver function markers

Mindray Perfect Plus 400 was used to measure the activities of aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine aminotransferase (ALT) in the serum. The results were given in units of U/L.

Oxidative stress indicators

To obtain the homogenate, liver tissue was homogenised in a homogeniser (Tissue Lyser II, Qiagen, Netherlands) in a solution of 1.15% KCl. The activity of glutathione peroxidase (GPx) was measured using Lawrence, Burk [14] procedure. The activity of superoxide dismutase (SOD) was determined using the method reported by Sun et al. [15]. The activity of both enzymes has been presented as U/g protein. The activity of catalase (CAT) was measured using the Aebi [16] protocol and has been presented as Katal/g protein. The content of glutathione (GSH) has been analysed using the Sedlak, Lindsay [17] technique. MDA level was measured as described by Placer et al. [18]. The GSH and MDA levels were measured in nmol/g tissue. The protein content of liver tissue was determined using the Lowry et al. [19].

Table 1 Primer sequences

Gene	Sequences (5'-3')	Length (bp)	Accession no
Bax	F: TTTCATCCAGGATCGAGCAG R: AATCATCCTCTGCAGCTCCA	154	NM_017059.2
Bcl-2	F: GACTTTGCAGAGATGTCCAG R: TCAGGTACTCAGTCATCCAC	214	NM_016993.2
Caspase-3	F: ACTGGAATGTCAGCTCGCAA R: GCAGTAGTCGCCTCTGAAGA	270	NM_012922.2
Apaf-1	F: ACCTGAGGTGTCAGGACC R: CCGTCGAGCATGAGCCAA	192	NM_023979.2
Nrf2	F: TTTGTAGATGACCATGAGTCGC R: TCCTGCCAAACTTGCTCCAT	161	NM_031789.2
HO-1	F: ATGTCACAGGATTTGTCCGA R: ATGGTACAAGGAGGCCATCA	144	NM_012580.2
Akt2	F: GAGTACTTGCCTCGACGGA R: CCATGAGGATGAGCTCGAAG	304	NM_017093.1
FOXO1	F: CAGCCAGGCACCTCATAACA R: TCAAGCGGTTTCATGGCAGAT	143	NM_001191846.3
MMP2	F: CTCTAGGAGAAGGACAAGTG R: CTCAAAGTTGTACGTGGTGG	158	NM_031054.2
MMP9	F: AGCTGGCAGAGGATTACCTG R: ATGATGGTGCCACTTGAGGT	230	NM_031055.2
MAPK14	F: GTGGCAGTGAAGAAGCTGTC R: GTCACCAGGTACACATCGTT	170	NM_031020.2
MAPK15	F: TGTTTGAGTCCATGGACACC R: GCATCCAATAGAACGTTGGC	169	NM_173331.2
JNK	F: GAATCAGACCCATGCTAAGC R: CCATGAGCTCCATGACTATG	149	NM_053829.2
GAPDH	F: GAGTATGTCGTGGAGTCTAC R: CAGGATGCATTGCTGACAAT	179	NM_017008.4

Gene expression analysis

In the first stage, total RNA was isolated from liver tissues of rats treated with MTX and morin. Total RNA isolation was performed using QIAzol Lysis Reagent (Qiagen, Cat: 79,306, Germany). In the next step, cDNAs were synthesized from total RNAs with the iScript™ cDNA Synthesis Kit (BIO-RAD, United States). At the last stage, the relative mRNA transcript levels of the genes [nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), Bcl-2-associated x protein (Bax), B-cell lymphoma-2 (Bcl-2), cysteine aspartate specific protease-3 (caspase-3), metalloproteinase-2 (MMP2), metalloproteinase-9 (MMP9), apoptotic protease activating factor-1 (Apaf1), forkhead box transcription factor O1 (FOXO1), c-Jun N-terminal kinase (JNK), mitogen-activated protein kinase 14 (MAPK14), MAPK15 and Akt2] whose sequences are given in Table 1 were analyzed by RT-PCR method. For this, a mix was prepared with the primers of the relevant genes, cDNAs and iTaq Universal SYBR Green Supermix (BIORAD) and the reaction was started in the ROTOR-GENE Q (Qiagen, Germany) device. According to Livak, Schmittgen [20], the acquired qRT-PCR data was analyzed using the comparative threshold (Ct) method. GAPDH was used as internal control.

Statistical analysis

The mean and standard error of the mean were used to express the findings (SEM). To compare groups, a one-way analysis of variance was used, followed by a Tukey's post-hoc test. The significance level was set at $p < 0.05$. For statistical analysis of the data, the package program SPSS version 20.0 (SPSS, Chicago, IL) was used.

Results

Liver function and oxidative stress parameters

In comparison to the control group, MTX caused a substantial increase in activity of serum AST, ALT and ALP ($p < 0.05$). In contrast to the only MTX injected group, morin treatment significantly reduced the activities of AST, ALT, and ALP in the MTX+Morin 50 and MTX+Morin 100 groups ($p < 0.05$). There was no discernible change between the control and the morin only treated group (Table 2).

Table 2 shows that MTX significantly reduced SOD, CAT, and GPx activities, as well as GSH levels, as compared to the untreated control ($p < 0.05$). In contrast to the MTX group, different oral doses of morin (50 and 100 mg/kg) effectively reversed MTX-induced reductions in GSH

Table 2 Effect of Morin on hepatic serum markers and oxidative stress biomarkers in MTX-induced hepatotoxicity

Parameters	Control	Morin	MTX	MTX+Morin-50	MTX+Morin-100
ALP (U/L)	39.12 ± 1.96 ^a	37.78 ± 1.39 ^a	74.32 ± 2.56 ^d	63.15 ± 2.19 ^c	50.06 ± 2.04 ^b
ALT (U/L)	41.03 ± 1.88 ^a	40.22 ± 1.59 ^a	77.15 ± 2.67 ^d	60.63 ± 2.38 ^c	52.96 ± 2.17 ^b
AST (U/L)	55.11 ± 2.23 ^a	54.34 ± 2.52 ^a	109.76 ± 3.91 ^d	90.39 ± 3.65 ^c	73.08 ± 4.03 ^b
MDA (nmol/g tissue)	29.55 ± 1.17 ^a	30.43 ± 3.88 ^a	47.02 ± 1.67 ^d	40.32 ± 1.16 ^c	34.87 ± 2.07 ^b
GSH (nmol/g tissue)	7.15 ± 0.22 ^d	7.30 ± 0.15 ^d	3.52 ± 0.11 ^a	4.46 ± 0.13 ^b	5.38 ± 0.12 ^c
CAT (katal/g protein)	56.20 ± 2.57 ^d	58.80 ± 1.55 ^d	33.97 ± 2.05 ^a	41.39 ± 2.11 ^b	47.72 ± 0.99 ^c
SOD (U/g tissue)	39.88 ± 1.41 ^d	40.21 ± 1.36 ^d	25.91 ± 1.26 ^a	30.00 ± 0.98 ^b	34.47 ± 0.94 ^c
GPx (U/g tissue)	34.63 ± 1.73 ^d	36.05 ± 1.59 ^d	19.95 ± 1.07 ^a	23.32 ± 0.98 ^b	28.40 ± 0.89 ^c

Different superscripts (a–d) in the same row indicate significant difference ($p < 0.05$) among groups




Fig. 1 Effects of morin and MTX treatments on Nrf-2/HO-1 mRNA expression levels in liver tissue. (A) Nrf-2 mRNA transcript levels, (B) HO-1 mRNA transcript levels. Values are expressed as mean ± SD. Different letters (a–d) on the columns show a statistical difference ($p < 0.05$)

content and SOD, CAT, and GPx activities ($p < 0.05$). MDA was used to analyse lipid peroxidation in liver and the results are reported in Table 2. When comparing the MTX-induced group to the control and just morin supplemented groups, there was a substantial increase in levels of hepatic MDA. When comparing to the MTX group, the MDA levels in the MTX+morin 50 and MTX+morin 100 groups were considerably lower ($p < 0.05$).

The expression profiles of Nrf2 and HO-1

By using qRT-PCR, the expression profiles of the Nrf2 and HO-1 genes in the hepatic tissue in the control and treatment groups were assessed. Only the group that received MTX had reduced expression levels of Nrf2 and HO-1 when compared to the control group (Fig. 1 A and B). The mRNA transcript levels of Nrf2 and HO-1 were found to be at the same level as the control in the morin-treated group. In comparison to the MTX group, Nrf2 and HO-1 gene

expression levels were higher in the MTX+morin 50 and MTX+morin 100 groups. In contrast to the MTX group, these expression levels were considerably lower ($p < 0.05$).

Morin alleviates the expression of apoptotic and anti-apoptotic genes triggered by MTX

The effects of MTX injection and morin treatment on mRNA transcript levels of Bax, Bcl2, Caspase-3 and Apaf1 in rat hepatic tissue were examined. When compared to the untreated control group, MTX supplementation significantly ($p < 0.05$) elevated mRNA levels of Bax, Caspase-3 and Apaf1 while their expression was downregulated in the MTX+morin 50 and MTX+morin 100 groups (Fig. 2 A–D). Furthermore, MTX treatment decreased Bcl-2 mRNA transcript levels, whereas supplementation with different dosages of morin increased its expression, suggesting that morin has an anti-apoptotic role in MTX-induced hepatic injury ($p < 0.05$).




Fig. 2 Effects of morin and MTX treatments on Bax, Bcl-2, Caspase-3 and Apaf-1 mRNA expression levels in liver tissue. (A) Bax mRNA transcript levels, (B) Bcl-2 mRNA transcript level, (C) Caspase-3

mRNA transcript levels, (D) Apaf-1 mRNA transcript levels. Values are expressed as mean \pm SD. Different letters (a–d) on the columns show a statistical difference ($p < 0.05$)

Morin has an effect on the levels of MAPK14 and MAPK15 mRNA transcripts in hepatic tissue

The effects of MTX treatment and morin supplementation on mRNA transcript levels of MAPK14 and MAPK15 in rat hepatic tissue were examined. When compared to the untreated control group, MTX injection significantly elevated mRNA levels of MAPK14 and MAPK15 while their expression was down-regulated in the MTX + morin 50 and MTX + morin 100 groups (Fig. 3 A and B) suggesting that morin has an ameliorative role in MTX-induced hepatic injury.

Morin has an effect on the levels of JNK, Akt2 and FOXO1 mRNA transcripts in hepatic tissue

Figure 3 C–E shows the effects of MTX and/or morin treatments on JNK, Akt2 and FOXO1 mRNA expression levels in hepatic tissue. The mRNA expression levels of JNK, Akt2 and FOXO1 were significantly up-regulated in the liver of MTX-induced rats according to our RT-PCR data. Morin (50 and 100 mg/kg) treatment, oppositely, reduced the mRNA transcripts levels of these markers in liver.




Fig. 3 Effects of morin and MTX treatments on MAPK 14, MAPK 15, JNK, Akt2 and FOXO1 mRNA expression levels in liver tissue. (A) MAPK 14 mRNA transcript levels, (B) MAPK 15 mRNA transcript level, (C) JNK mRNA transcript levels, (D) Akt2 mRNA transcript

levels, (E) FOXO1 mRNA transcript levels. Values are expressed as mean \pm SD. Different letters (a–d) on the columns show a statistical difference ($p < 0.05$)




Fig. 4 Effects of morin and MTX treatments on MMP2 and MMP9 mRNA transcript levels in liver tissue. (A) MMP2 mRNA transcript levels, (B) MMP2 mRNA transcript levels. Values are expressed as mean \pm SD. Different letters (a–d) on the columns show a statistical difference ($p < 0.05$)

Morin has an effect on the levels of MMP-2 and MMP-9 mRNA transcripts in hepatic tissue

The expression profiles of MMP2 and MMP9 genes in the hepatic tissue were evaluated by qRT-PCR in the control and treatment groups. Figure 4 A and B shows that MTX

significantly up-regulated expression levels of MMP2 and MMP9 in the liver as compared to the control group. In contrast to the MTX group, supplementation of morin (50 and 100 mg/kg) effectively reversed MTX-induced upregulations in MMP2 and MMP9 levels.

Discussion

MTX is an antimetabolite therapeutics that is extensively used as an anticancer and immune-suppressive drug, although its therapeutic efficacy is hampered by organ toxicities [21]. One of the most dangerous side effects of long-term MTX treatment is hepatotoxicity, which is caused by the accumulation of 7-hydroxymethotrexate, the drug's primary metabolite [22]. Because of the importance of drug-induced hepatic toxicity in clinical medicine, researchers are increasingly interested in gaining a better understanding of the toxicity, specifically the processes and ways to reduce the occurrence of these nasty side effects. In this study, the ameliorative effects of morin on MTX-induced hepatotoxicity were evaluated.

Hepatic dysfunction has been linked to MTX intoxication, as evident by raised serum activity of the ALT, ALP and AST enzymes [23]. In this study, serum marker enzymes of hepatocellular injury were evaluated. Under normal circumstances, these enzymes are mostly found in the hepatic tissue. They are frequently released into the circulation for the duration of hepatocyte necrosis or membrane damage. AST and ALT are found in periportal hepatocytes and engage in transamination reactions during amino acid metabolism [24]. However, their serum activity have been shown to be enhanced following cellular membrane injury and leaking. As a result, the considerable rise in levels of these enzymes following MTX administration is revealing the disturbed membrane permeability in the treated rats, which is associated with hepatic injury. However, the noteworthy reductions in serum AST, ALT and ALP levels after morin administration to MTX-treated rats suggests that morin provides hepatoprotection against MTX-induced liver injury. In previous studies, it has been shown that morin treatment reduces AST, ALT and ALP enzyme levels in hepatotoxicity caused by chemotherapeutic drugs such as doxorubicin and ifosfamide [12, 25].

Hepatic impairment caused by MTX have been linked to oxidative damage. MTX causes oxidative stress at the cellular level by producing free radicals and ROS [26]. LPO, alterations in antioxidant machinery, DNA damage, alteration in gene expressions and apoptosis are all symptoms of oxidative stress [27]. The organism has evolved numerous mechanisms to defend itself against oxidative stress. These processes include antioxidant enzymes like SOD, CAT, and GPx, as well as the non-enzymatic antioxidant glutathione [28, 29]. Several independent studies have been conducted on antioxidants and their importance in preventing oxidative injury and the cellular damage that comes with it, as well as the critical roles of SOD, CAT and GPx [30, 31]. The effects of morin supplementation on oxidative stress indicators in MTX-induced hepatotoxicity were studied in this work. The

findings demonstrated that MTX administration increased MDA levels and decreased GSH levels as well as SOD, CAT, and GPx activities in hepatic tissues, while morin therapy mitigated these effects.

MTX has also been reported to decrease Nrf2 binding activity and suppresses Nrf2 expression in the livers of MTX-treated mice [32]. This decrease in Nrf2 activity may be linked to a decrease in the liver's anti-oxidant status. We measured Nrf2-HO-1 pathway mRNA expression to further understand the processes underlying morin's protective impact against MTX-induced liver damage. Nrf2 has been reported to be activated by cytoplasmic Kelch-like ECH-associated protein 1 and stimulates the production of antioxidant genes in response to oxidative stress [33]. Nrf2 regulates the transcription of HO-1, an important cellular antioxidant enzyme [34]. HO-1 can reduce inflammation, reduce oxidative stress, and slow the rate of apoptosis all at the same time. Collectively, our findings suggest that HO-1 induction through Nrf2 activation may play a role in morin's cytoprotection against MTX-induced oxidative stress.

Apoptosis is a type of biological cellular death that is vital for the formation and maintenance of homeostatic balance in human and animals. Pro-apoptotic proteins like Bax, caspase-3 and anti-apoptotic factors like Bcl-2 strictly regulate it [35]. According to the reports, MTX causes liver damage, which may be directly related to pro-apoptotic protein activation. In the current study, we use the quantitative real time PCR method to assess three apoptotic markers: Bax, caspase-3 and Apaf-1 and anti-apoptotic Bcl-2. Generally, the mitochondrial apoptosis process is initiated by Bax, which also damages DNA and activates caspase-3 [36]. The intrinsic or mitochondrial mechanism of apoptosis uses the protein Apaf-1, which oligomerizes in response to the release of cytochrome c and creates the huge complex known as an apoptosome. The apoptosome recruits and activates procaspase-9, a mitochondrial pathway initiator caspase, which results in the processing of caspase-3 downstream [37]. In good agreement with present findings, Ebrahimi et al. showed that MTX administration was associated with increased caspase-3, caspase-9 and Bax expression and decreased Bcl-2 expression in the liver of rats [38]. The findings of the current study are consistent with previous findings regarding Bax, caspase-3, Apaf-1 and Bcl-2 regulation. Morin dramatically mitigated Bax, caspase-3, Apaf-1 and Bcl-2 expressions to a level that is comparable to the control.

One of the key elements of the signaling cascade that controls a variety of cellular functions, including cell division, developmental programs, hormone responses, and biotic and abiotic stress responses, is the MAPK pathway [39]. The most lately discovered atypical MAPK and one that has received the least attention is called

MAPK15. Studies on the function of MAPK15 in many different cells and model organisms show that MAPK15 is involved in a wide range of cellular processes, including stimulating cell division and protein secretion; controlling cell division, cell transformation and apoptosis [40]. MAPK14 is a osmoregulatory protein JNK, an important branch of the MAPKs, plays an important function in the apoptosis triggered by TNF- α that is induced via exposure to a variety of cellular stresses [41]. One of the biochemical mechanisms leading to the adverse effects of MTX is p38 MAPK-signaling pathway is especially associated with a pulmonary inflammatory response [42]. The findings of the current study are consistent with previous findings regarding MAPK signaling regulation [43]. Morin dramatically mitigated effects of these to a level that is comparable to the control in parallel to literature [44].

The Akt/PKB isoforms have different roles in animals, with Akt2 primarily regulating metabolic signaling and Akt1 regulating growth and survival [45]. FOXO1 is a member of the forkhead transcription factor family, which is involved in a variety of biological functions such as DNA repair, apoptosis, cell cycle arrest, and resistance to oxidative stress [46]. The Akt-FoxO1 signaling pathway plays an essential role during liver regeneration [47]. The mRNA expression levels of Akt2 and FOXO1 were significantly upregulated in the liver of MTX-induced rats according to our RT-PCR data. Morin (50 and 100 mg/kg) treatment, on the other hand, reduced the levels of these markers. In a different study, morin inhibits glucose production in cultured HepG2 cells inactivating FOXO1 and Akt [48].

Extracellular matrix proteins are broken down and synthesized more quickly by metalloproteinases (MMPs), a class of zinc-dependent endopeptidases. Gelatinase MMP-2 and MMP-9 are two examples of this category of enzymes. High levels of these gelatinases in the bloodstream are linked to an inflammatory process [49]. MMPs have been associated with the pathophysiology of the MTX [50]. In current study, we demonstrated that serum MMP-2 and MMP-9 levels increased after MTX administration in consistent with the literature. In contrast to the MTX group, co-supplementation of morin (50 and 100 mg/kg) effectively reversed MTX-induced upregulations in MMP-2 and MMP-9 levels. The impacts of morin on MMP-2 and MMP-9 expressions were investigated in other studies as well [51, 52]. In this study, we have demonstrated ability of morin in mitigating MTX-induced hepatic injury.

Conclusion

In this study, morin mitigated oxidative stress and apoptosis, down-regulated mRNA levels of caspase-3, Bax, Apaf-1, MMP-2, MMP-9, MAPK14, MAPK15, JNK, Akt2 and FOXO1 genes, reduced ALT, ALP and AST levels in MTX-induced hepatic tissue. All data obtained from the study reveal the ameliorative effects of morin supplementation towards MTX-induced liver damage.

Authors' contributions All authors contributed to the study conception and design. HEK, CG and SK performed the experiments. CC and ED designed the present study. FMK, AA and CG analyzed the data. HEK and CC drafted the manuscript. CC, AA and FMK revised the manuscript.

Funding Part of this study was supported by the Bingol University Scientific Research Project (BAP-FEF.2021.006) and another part was supported by the authors.

Data Availability All the data are available with the corresponding author. The data will be provided on request.

Declarations

Ethical approval Experimental and animal-care protocols were approved by the Animal Experimentation Ethics Committee of Bingol University (Protocol No: 2022-E.66052).

Conflict of interest The authors declare no competing interests.

References

1. Bedoui Y, Guillot X, Sélambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, Ralandison S, Gasque P (2019) Methotrexate an Old Drug with New Tricks. *Int J Mol Sci* 20 (20)
2. Friedman B, Cronstein B (2019) Methotrexate mechanism in treatment of rheumatoid arthritis. *Jt Bone Spine* 86(3):301–307
3. Cronstein BN, Aune TM (2020) Methotrexate and its mechanisms of action in inflammatory arthritis. *Nat Rev Rheumatol* 16(3):145–154
4. Dogra A, Gupta D, Bag S, Ahmed I, Bhatt S, Nehra E, Dhiman S, Kumar A, Singh G, Abdullah ST, Sangwan PL, Nandi U (2021) Glabridin ameliorates methotrexate-induced liver injury via attenuation of oxidative stress, inflammation, and apoptosis. *Life Sci* 278:119583
5. Kandemir FM, Kucukler S, Caglayan C, Gur C, Batil AA, Gülçin İ (2017) Therapeutic effects of silymarin and naringin on methotrexate-induced nephrotoxicity in rats: biochemical evaluation of anti-inflammatory, antiapoptotic, and anti-autophagic properties. *J Food Biochem* 41(5):e12398
6. Aslankoc R, Ozmen O, Yalcin A (2022) Astaxanthin ameliorates damage to the cerebral cortex, hippocampus and cerebellar cortex caused by methotrexate. *Biotech Histochem* 97(5):382–393
7. Kuzu M, Kandemir FM, Yildirim S, Kucukler S, Caglayan C, Turk E (2018) Morin attenuates doxorubicin-induced heart and brain damage by reducing oxidative stress, inflammation and apoptosis. *Biomed Pharmacother* 106:443–453
8. Madhana KVA, Kasala RM, Samudrala ER, Lahkar PK, Gogoi M R (2016) Morin Hydrate mitigates Cisplatin-Induced Renal

- and hepatic Injury by impeding Oxidative/Nitrosative stress and inflammation in mice. *J Biochem Mol Toxicol* 30(12):571–579
9. Rajput SA, Wang X-q, Yan H-C (2021) Morin hydrate: a comprehensive review on novel natural dietary bioactive compound with versatile biological and pharmacological potential. *Biomed Pharmacother* 138:111511
 10. Solairaja S, Andrabi MQ, Dunna NR, Venkatabalasubramanian S (2021) Overview of Morin and its complementary role as an adjuvant for Anticancer Agents. *Nutr Cancer* 73(6):927–942
 11. Kandemir FM, Yıldırım S, Kucukler S, Caglayan C, Darendelioglu E, Dortbudak MB (2020) Protective effects of morin against acrylamide-induced hepatotoxicity and nephrotoxicity: a multi-biomarker approach. *Food Chem Toxicol* 138:111190
 12. Kuzu M, Yıldırım S, Kandemir FM, Küçükler S, Çağlayan C, Türk E, Dörtbudak MB (2019) Protective effect of morin on doxorubicin-induced hepatorenal toxicity in rats. *Chem Biol Interact* 308:89–100
 13. Hassanein EHM, Shalkami A-GS, Khalaf MM, Mohamed WR, Hemeida RAM (2019) The impact of Keap1/Nrf2, P38MAPK/NF- κ B and Bax/Bcl2/caspase-3 signaling pathways in the protective effects of berberine against methotrexate-induced nephrotoxicity. *Biomed Pharmacother* 109:47–56
 14. Lawrence RA, Burk RF (1976) Glutathione peroxidase activity in selenium-deficient rat liver. *Biochem Biophys Res Commun* 71(4):952–958
 15. Sun Y, Oberley LW, Li Y (1988) A simple method for clinical assay of superoxide dismutase. *Clin Chem* 34(3):497–500
 16. Aebi H (1984) [13] catalase in vitro. *Methods Enzymol* 105:121–126
 17. Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. *Anal Biochem* 25(1):192–205
 18. Placer ZA, Cushman LL, Johnson BC (1966) Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems. *Anal Biochem* 16(2):359–364
 19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. *J Biol Chem* 193(1):265–275
 20. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 – $\Delta\Delta$ CT method. *Methods* 25(4):402–408
 21. Katturajan R, Rasool SV, Evan Prince M S (2021) Molecular toxicity of methotrexate in rheumatoid arthritis treatment: a novel perspective and therapeutic implications. *Toxicology* 461:152909
 22. West SG (1997) Methotrexate Hepatotoxicity. *Rheum Dis Clin North Am* 23(4):883–915
 23. Roghani M, Kalantari H, Khodayar MJ, Khorsandi L, Kalantar M, Goudarzi M, Kalantar H (2020) Alleviation of liver dysfunction, oxidative stress and inflammation underlies the Protective Effect of Ferulic Acid in Methotrexate-Induced Hepatotoxicity. *Drug Des Devel Ther* 14:1933–1941
 24. Paunovic J, Vucevic D, Radosavljevic T, Pantic S, Veskovic M, Pantic I (2019) Gray-level co-occurrence matrix analysis of chromatin architecture in periportal and perivenous hepatocytes. *Histochem Cell Biol* 151(1):75–83
 25. Özdemir S, Kucukler S, Çomaklı S, Kandemir FM (2022) The protective effect of Morin against ifosfamide-induced acute liver injury in rats associated with the inhibition of DNA damage and apoptosis. *Drug Chem Toxicol* 45(3):1308–1317
 26. Kalantar M, Kalantari H, Goudarzi M, Khorsandi L, Bakhit S, Kalantar H (2019) Crocin ameliorates methotrexate-induced liver injury via inhibition of oxidative stress and inflammation in rats. *Pharmacol Rep* 71(4):746–752
 27. Klaunig JE (2018) Oxidative stress and Cancer. *Curr Pharm Des* 24(40):4771–4778
 28. Eldutar E, Kandemir FM, Kucukler S, Caglayan C (2017) Restorative effects of Chrysin pretreatment on oxidant–antioxidant status, inflammatory cytokine production, and apoptotic and autophagic markers in acute paracetamol-induced hepatotoxicity in rats: an experimental and biochemical study. *J Biochem Mol Toxicol* 31(11):e21960
 29. Küçükler S, Çomaklı S, Özdemir S, Çağlayan C, Kandemir FM (2021) Hesperidin protects against the chlorpyrifos-induced chronic hepato-renal toxicity in rats associated with oxidative stress, inflammation, apoptosis, autophagy, and up-regulation of PARP-1/VEGF. *Environ Toxicol* 36(8):1600–1617
 30. Caglayan C, Temel Y, Kandemir FM, Yildirim S, Kucukler S (2018) Naringin protects against cyclophosphamide-induced hepatotoxicity and nephrotoxicity through modulation of oxidative stress, inflammation, apoptosis, autophagy, and DNA damage. *Environ Sci Pollut Res* 25(21):20968–20984
 31. Kucukler S, Darendelioglu E, Caglayan C, Ayna A, Yildirim S, Kandemir FM (2020) Zingerone attenuates vancomycin-induced hepatotoxicity in rats through regulation of oxidative stress, inflammation and apoptosis. *Life Sci* 259:118382
 32. Abo-Haded HM, Elkablawy MA, Al-johani Z, Al-ahmadi O, El-Agamy DS (2017) Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity. *PLoS ONE* 12(3):e0174295
 33. Yardım A, Kandemir FM, Çomaklı S, Özdemir S, Caglayan C, Kucukler S, Çelik H (2021) Protective Effects of Curcumin against Paclitaxel-Induced spinal cord and sciatic nerve injuries in rats. *Neurochem Res* 46(2):379–395
 34. Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J (2016) Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. *Cell Mol Life Sci* 73(17):3221–3247
 35. Yang B, Johnson TS, Thomas GL, Watson PF, Wagner B, Furness PN, El Nahas AM (2002) A shift in the Bax/Bcl-2 balance may activate caspase-3 and modulate apoptosis in experimental glomerulonephritis. *Kidney Int* 62(4):1301–1313
 36. Cregan SP, MacLaurin JG, Craig CG, Robertson GS, Nicholson DW, Park DS, Slack RS (1999) Bax-dependent Caspase-3 activation is a key determinant in p53-Induced apoptosis in neurons. *J Neurosci* 19(18):7860
 37. Shakeri R, Kheirollahi A, Davoodi J (2017) Apaf-1: regulation and function in cell death. *Biochimie* 135:111–125
 38. Ebrahimi R, Sepand MR, Seyednejad SA, Omidi A, Akbariani M, Gholami M, Sabzevari O (2019) Ellagic acid reduces methotrexate-induced apoptosis and mitochondrial dysfunction via up-regulating Nrf2 expression and inhibiting the I κ B α /NF κ B in rats. *DARU J Pharm Sci* 27(2):721–733
 39. Singh A, Nath O, Singh S, Kumar S, Singh IK (2018) Genome-wide identification of the MAPK gene family in chickpea and expression analysis during development and stress response. *Plant Gene* 13:25–35
 40. Lau ATY, Xu Y-M (2019) Regulation of human mitogen-activated protein kinase 15 (extracellular signal-regulated kinase 7/8) and its functions: a recent update. *J Cell Physiol* 234(1):75–88
 41. Madkour MM, Anbar HS, El-Gamal MI (2021) Current status and future prospects of p38 α /MAPK14 kinase and its inhibitors. *Eur J Med Chem* 213:113216
 42. Kim Y-J, Song M, Ryu J-C (2009) Mechanisms underlying methotrexate-induced pulmonary toxicity. *Expert Opin Drug Saf* 8(4):451–458
 43. Spurlock Iii CF, Tossberg JT, Fuchs HA, Olsen NJ, Aune TM (2012) Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. *Arthritis Rheum* 64(6):1780–1789
 44. Kucukler S, Caglayan C, Darendelioglu E, Kandemir FM (2020) Morin attenuates acrylamide-induced testicular toxicity in rats by regulating the NF- κ B, Bax/Bcl-2 and PI3K/Akt/mTOR signaling pathways. *Life Sci* 261:118301

45. Zhou G-L, Tucker DF, Bae SS, Bhatheja K, Birnbaum MJ, Field J (2006) Opposing roles for Akt1 and Akt2 in Rac/Pak signaling and cell migration. *J Biol Chem* 281(47):36443–36453
46. Xiao E, Graves DT (2015) Impact of diabetes on the protective role of FOXO1 in Wound Healing. *J Dent Res* 94(8):1025–1026
47. Pauta M, Rotllan N, Fernández-Hernando A, Langhi C, Ribera J, Lu M, Boix L, Bruix J, Jimenez W, Suárez Y, Ford DA, Baldán A, Birnbaum MJ, Morales-Ruiz M, Fernández-Hernando C (2016) Akt-mediated foxo1 inhibition is required for liver regeneration. *Hepatology* 63(5):1660–1674
48. Paoli P, Cirri P, Caselli A, Ranaldi F, Bruschi G, Santi A, Camici G (2013) The insulin-mimetic effect of Morin: a promising molecule in diabetes treatment. *Biochim Biophys Acta - Gen Subj* 1830(4):3102–3111
49. García-Salazar LF, Ribeiro JAM, Cunha JE, Mattiello SM, Luiz Russo T (2021) Serum activity of matrix metalloproteinase-2 and -9 is increased in chronic post-stroke individuals: a cross-sectional exploratory study. *Top Stroke Rehabil*:1–11
50. Bilginaylar K, Aykac A, Sayiner S, Özkayalar H, Şehirli A (2022) Evaluation of the antiapoptotic and anti-inflammatory properties of chitosan in methotrexate-induced oral mucositis in rats. *Mol Biol Rep* 49(4):3237–3245
51. Sivaramakrishnan V, Niranjali Devaraj S (2009) Morin regulates the expression of NF- κ B-p65, COX-2 and matrix metalloproteinases in diethylnitrosamine induced rat hepatocellular carcinoma. *Chem Biol Interact* 180(3):353–359
52. Shin S-S, Ko M-C, Noh D-H, Hwang B, Park Y, Park SL, Kim W-J, Moon S-K (2018) Morin inhibits PDGF-induced proliferation, migration, and invasion of vascular smooth muscle cells via modulating p27KIP1, AKT, and MMP-9 activities. *Gen Physiol Biophys* 37(6):633–645

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.